Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 2/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.41 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.34 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.34 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.34 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2803318 | 0.86 | PTGES (0.54) | PTGESEPHX2 | |
| SCHEMBL2802164 | 0.85 | PTGES (0.51) | PTGESEPHX2ALKBH2ALKBH3FTO | |
| SCHEMBL2803302 | 0.82 | PTGES (0.53) | PTGESEPHX2 | |
| SCHEMBL2803062 | 0.82 | EPHX2 (0.44) | PTGESEPHX2ALKBH2ALKBH3FTO | |
| SCHEMBL2807758 | 0.82 | PTGES (0.48) | PTGESALKBH2ALKBH3FTO | |
| SCHEMBL2805827 | 0.80 | PTGES (0.48) | PTGESALKBH2ALKBH3 | |
| SCHEMBL2802188 | 0.79 | PTGES (0.54) | PTGES | |
| SCHEMBL979479 | 0.79 | PTGES (0.46) | PTGESALKBH2ALKBH3FTOF7 | |
| SCHEMBL2802092 | 0.78 | PTGES (0.50) | PTGESEPHX2 | |
| SCHEMBL13066259 | 0.78 | EPHX2 (0.40) | PTGESEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | claimed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | claimed |
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | PTGES 9/4885EPHX2 182/4885ALKBH2 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.